Literature DB >> 11716069

Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.

W Wick1, M Platten, M Weller.   

Abstract

Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that selectively degrade components of the extracellular matrix. MMPs are implicated in tumor cell invasion because they mediate the breakdown of the basal membrane. In addition, they seem to be important for the creation and maintenance of a microenvironment that facilitates tumor cell survival. Among the essential characteristics of human malignant gliomas are infiltrative growth, angiogenesis and suppression of antitumor immune surveillance. Transforming growth factor-beta (TGF-beta) is intimately involved in the regulation of these processes. We have previously demonstrated that TGF-beta promotes the migration of LN- 18 and LN-229 glioma cells via a process that may involve the upregulation of alphaVbeta3 integrin expression. Furthermore, we have defined a novel pathway for hepatocyte growth factor (HGF)-induced glioma cell migration and invasion which requires the induction of TGF-beta2 expression. Here, we demonstrate that TGF-beta2 induces MMP-2 expression and suppresses tissue inhibitor of metalloproteinases (TIMP)-2 expression and that concentration-dependently promotes the invasion of U87MG and LN-229 glioma cells in a matrigel invasion assay. Similarly, ectopic expression of the anti-apoptotic BCL-x, protein leads to enhanced matrigel invasion by LN-18 and LN-229 glioma cells. We outline the possible interrelations of TGF-beta, proteins of the BCL-2 family, integrins and metalloprotease activity. By virtue of its promotion of glioma invasion and its growth regulatory and immunomodulatory properties. TGF-beta continues to be one of the most promising targets for the experimental therapy of human malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716069     DOI: 10.1023/a:1012209518843

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  60 in total

1.  Transforming growth factor-beta1 stimulates contraction of human glioblastoma cell-mediated collagen lattice through enhanced alpha2 integrin expression.

Authors:  K Miyake; S Kimura; M Nakanishi; A Hisada; M Hasegawa; S Nagao; Y Abe
Journal:  J Neuropathol Exp Neurol       Date:  2000-01       Impact factor: 3.685

2.  In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.

Authors:  S Mohanam; S K Chintala; Y Go; A Bhattacharya; B Venkaiah; D Boyd; Z L Gokaslan; R Sawaya; J S Rao
Journal:  Oncogene       Date:  1997-03-20       Impact factor: 9.867

3.  Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.

Authors:  B A Teicher; M Ikebe; G Ara; S R Keyes; R S Herbst
Journal:  In Vivo       Date:  1997 Nov-Dec       Impact factor: 2.155

4.  Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes.

Authors:  A Olofsson; K Miyazono; T Kanzaki; P Colosetti; U Engström; C H Heldin
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.

Authors:  M Weller; J Rieger; C Grimmel; E G Van Meir; N De Tribolet; S Krajewski; J C Reed; A von Deimling; J Dichgans
Journal:  Int J Cancer       Date:  1998-12-18       Impact factor: 7.396

Review 6.  Interactions of glioma cells and extracellular matrix.

Authors:  W Paulus; J C Tonn
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  BCL-2 promotes migration and invasiveness of human glioma cells.

Authors:  W Wick; S Wagner; S Kerkau; J Dichgans; J C Tonn; M Weller
Journal:  FEBS Lett       Date:  1998-12-04       Impact factor: 4.124

8.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Authors:  S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck
Journal:  Cell       Date:  1998-06-26       Impact factor: 41.582

9.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.

Authors:  W M Grady; A Rajput; L Myeroff; D F Liu; K Kwon; J Willis; S Markowitz
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

10.  Matrix metalloproteinase-2 activation modulates glioma cell migration.

Authors:  E I Deryugina; M A Bourdon; G X Luo; R A Reisfeld; A Strongin
Journal:  J Cell Sci       Date:  1997-10       Impact factor: 5.285

View more
  101 in total

1.  Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Authors:  Shiv K Singh; Roberto Fiorelli; Robert Kupp; Sindhu Rajan; Emily Szeto; Costanza Lo Cascio; Cecile L Maire; Yu Sun; John A Alberta; Jennifer M Eschbacher; Keith L Ligon; Michael E Berens; Nader Sanai; Shwetal Mehta
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

2.  Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Invest New Drugs       Date:  2015-08-15       Impact factor: 3.850

Review 3.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

4.  Versican isoform V1 regulates proliferation and migration in high-grade gliomas.

Authors:  Julia Onken; Sylvia Moeckel; Petra Leukel; Verena Leidgens; Fusun Baumann; Ulrich Bogdahn; Arabel Vollmann-Zwerenz; Peter Hau
Journal:  J Neurooncol       Date:  2014-07-27       Impact factor: 4.130

Review 5.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas.

Authors:  Peter Hau; Leoni A Kunz-Schughart; Petra Rümmele; Füsun Arslan; Anett Dörfelt; Horst Koch; Annette Lohmeier; Birgit Hirschmann; Adolf Müller; Ulrich Bogdahn; Anja-Katrin Bosserhoff
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

7.  A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.

Authors:  Ye Song; Zheng Hu; Hao Long; Yuping Peng; Xi'an Zhang; Tianshi Que; Shihao Zheng; Zhiyong Li; Gang Wang; Liu Yi; Zhen Liu; Weiyi Fang; Songtao Qi
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

8.  Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

Authors:  Ruman Rahman; Stuart Smith; Cheryl Rahman; Richard Grundy
Journal:  J Oncol       Date:  2010-04-11       Impact factor: 4.375

9.  Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures.

Authors:  Carsten Hagemann; Jelena Anacker; Stefanie Haas; Daniela Riesner; Beate Schömig; Ralf-Ingo Ernestus; Giles H Vince
Journal:  BMC Res Notes       Date:  2010-11-10

10.  Exploratory Visual Analysis of statistical results from microarray experiments comparing high and low grade glioma.

Authors:  David M Reif; Mark A Israel; Jason H Moore
Journal:  Cancer Inform       Date:  2007-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.